Early last week, the founder of Insys Therapeutics resigned from his company’s board after being hit with racketeering and fraud charges. Essentially, the feds are alleging he and other Insys execs participated in a bribe scheme to get doctors to prescribe more of their synthetic opioid Subsys. This comes after President Trump did finally follow through on his declaration of an impending declaration of a state of emergency for the crisis. That means the US government is getting serious about a crackdown—here are some ways that could take shape. The FDA certainly didn’t mince words about getting serious either, with Commissioner Scott Gottlieb saying it would be taking actions that could be “disruptive” and “uncomfortable” for drug makers.